PRWeb The Leader Press Release Distribution

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for June 5, 2007 Subscribe to this News Feed    
 

Avandia Resource Website

Avandia Lawyers Williams Bailey launch an Avandia Resource Website

Houston, TX (PRWEB) June 5, 2007 -- In reaction to a study (Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes-Published at frequently asked questions in regards to Avandia intended to be a resource for frequently asked questions related to Avandia. Williams Bailey is led by Attorneys John Eddy Williams and Steve Kherkerk, and has 26 attorneys and over 120 support staff and has worked in the area pharmaceutical litigation for over 24 years.

Avandia (rosiglitazone) is made by GlaxoSmithKline and is prescribed as a treatment for Type 2 Diabetes for those who do not take daily insulin injections. Avandia was approved by the FDA in 1999 over the past 8 years over 60 million prescriptions have been written for the drug. According to the study by Dr. Steven Nissen and Kathy Wolksi who evaluated 42 studies that looked at 28,000 patients of whom were 15,560 were taking Avandia. The researchers found the risk of a heart attack increased 43 percent among those taking Avandia. The researches also found that there is a 64 percent increased risk of dying from cardiovascular causes while taking the drug. The findings of the study that will appear in the June 14 issue of the New England Journal of Medicine, but because of the serious implications of the study the New England Journal of Health released the findings early. The FDA reported that Avandia is the same class as Rezulin which in rare cases has been associated with serious liver injury including liver failure or death. The FDA also reports that there is a risk associated with Avandia of blood sugar becoming dangerously low. Paul Diggle a pharmaceutical analyst at Nomura Code Securities based in London commented, "Unless this can be refuted, which I rather doubt, then this is going to seriously damage one of the cornerstones of Glaxo going forward."

Unless this can be refuted, which I rather doubt, then this is going to seriously damage one of the cornerstones of Glaxo going forward.
###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/RW1wdC1JbnNlLUNvdXAtU2luZy1UaGlyLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


Other Releases by this Member
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION
Rodney Organ
The Search Engine Guys
5125734183
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appearshere.
 
Close Move